Parathyroid Carcinoma: Incidence, Survival Analysis, and Management: A Study from the SEER Database and Insights into Future Therapeutic Perspectives
- PMID: 35326576
- PMCID: PMC8946517
- DOI: 10.3390/cancers14061426
Parathyroid Carcinoma: Incidence, Survival Analysis, and Management: A Study from the SEER Database and Insights into Future Therapeutic Perspectives
Abstract
Introduction: Parathyroid carcinoma (PC) is an extremely rare entity, with a frequency of 0.005% of all malignancies. Most data related to this rare disease are limited to case series and a few database studies. We present a large database study that aims to investigate the demographic, clinical, and pathological factors, prognosis, and survival of PC. Methods: Data of parathyroid carcinoma were extracted from the Surveillance, Epidemiology, and End Results (SEER) diagnosed between 1975 and 2016. Results: PC had a slightly higher incidence in men (52.2%, p < 0.005), the majority of cases affected Caucasians (75.4%, p < 0.005), and the mean age at diagnosis was 62 years. Histologically, 99.7% were adenocarcinomas not otherwise specified (p < 0.005), well-differentiated (p < 0.005), and 2−4 cm (p < 0.001) in size among the patients with available data. In cases with staging provided, most PC were organ-confined (36.8%, p < 0.001). Lymph nodes were positive in 25.2% of cases where lymph node status was reported. The main treatment modality was surgery (97.2%), followed by radiation alone (2%), and very few received chemotherapy alone (0.8%), p < 0.005. Five-year follow-up was available for 82.7% of the cases. Those who underwent surgery only or radiation alone had 5-year survivals of 83.8% and 72.2%, respectively (p < 0.037). Multivariable analysis identified tumor size >4 cm, age > 40 years, male sex, Caucasian race, distant spread, and poorly differentiated grade as independent risk factors for mortality (p < 0.001). Conclusion: PC is a very rare tumor mostly affecting Caucasian individuals in the fifth decade. Older age, poor histologic differentiation, and distant metastasis are associated with a worse prognosis. Surgical resection offers the best survival outcome. To better understand the pathogenesis and factors affecting survival, all PC patients should be enrolled in national and international registries.
Keywords: SEER program; cancer staging; incidence; mortality; parathyroid carcinoma; survival.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Incidence, Survival Analysis and Future Perspective of Primary Peritoneal Mesothelioma (PPM): A Population-Based Study from SEER Database.Cancers (Basel). 2022 Feb 14;14(4):942. doi: 10.3390/cancers14040942. Cancers (Basel). 2022. PMID: 35205689 Free PMC article.
-
Klatskin Tumor in the Light of ICD-O-3: A Population-Based Clinical Outcome Study Involving 1,144 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (2001-2012).Cureus. 2021 Oct 21;13(10):e18941. doi: 10.7759/cureus.18941. eCollection 2021 Oct. Cureus. 2021. PMID: 34815893 Free PMC article.
-
20-Year Comparative Survival and Mortality of Cancer of the Stomach by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes: A Systematic Review of 157,258 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2019;48(1):5-23. doi: 10.17849/insm-48-1-1-19.1. Epub 2019 Oct 14. J Insur Med. 2019. PMID: 31609640
-
Acinic Cell Carcinoma in the 21st Century: A Population-Based Study from the SEER Database and Review of Recent Molecular Genetic Advances.Cancers (Basel). 2023 Jun 27;15(13):3373. doi: 10.3390/cancers15133373. Cancers (Basel). 2023. PMID: 37444484 Free PMC article.
-
Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2018;47(4):203-211. doi: 10.17849/insm-47-04-1-9.1. Epub 2019 Jan 22. J Insur Med. 2018. PMID: 30668210
Cited by
-
Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.Int J Mol Sci. 2022 Jun 23;23(13):6981. doi: 10.3390/ijms23136981. Int J Mol Sci. 2022. PMID: 35805976 Free PMC article. Review.
-
Mediastinal Parathyroid Cancer.Cancers (Basel). 2022 Nov 28;14(23):5852. doi: 10.3390/cancers14235852. Cancers (Basel). 2022. PMID: 36497335 Free PMC article.
-
Margin Free Resection Achieves Excellent Long Term Outcomes in Parathyroid Cancer.Cancers (Basel). 2022 Dec 29;15(1):199. doi: 10.3390/cancers15010199. Cancers (Basel). 2022. PMID: 36612195 Free PMC article.
-
Intrathyroidal parathyroid carcinoma masquerading as a cystic thyroid nodule: a case report.Gland Surg. 2025 May 30;14(5):968-973. doi: 10.21037/gs-2025-69. Epub 2025 May 20. Gland Surg. 2025. PMID: 40546841 Free PMC article.
-
Pembrolizumab with external radiation therapy effectively controlled TMB-high unresectable recurrent parathyroid cancer: a case report with review of literature.Endocr J. 2024 Nov 1;71(11):1069-1075. doi: 10.1507/endocrj.EJ24-0126. Epub 2024 Jul 10. Endocr J. 2024. PMID: 38987211 Free PMC article. Review.
References
-
- Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: A National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancers. 1999;86:538–544. doi: 10.1002/(SICI)1097-0142(19990801)86:3<538::AID-CNCR25>3.0.CO;2-K. - DOI - PubMed
-
- Wassif W.S., Moniz C.F., Friedman E., Wong S., Weber G., Nordenskjöld M., Peters T.J., Larsson C. Familial isolated hyperparathyroidism: A distinct genetic entity with an increased risk of parathyroid cancer. J. Clin. Endocrinol. Metab. 1993;77:1485–1489. doi: 10.1210/jcem.77.6.7903311. - DOI - PubMed
LinkOut - more resources
Full Text Sources